Colony Stimulating Factors (CSF) Prior Authorization
Customize your policy alerts
Sign up for all mediviewcurative policy alerts
Know when mediviewcurative releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior authorization coverage criteria for short- and long-acting colony stimulating factor drugs (e.g., filgrastim, pegfilgrastim) for Curative Health Plan members; applies to provider requests for CSF medications.
No material clinical or coverage changes in this revision.
Coverage Criteria for Colony Stimulating Factors
Initial Therapy — Short-acting CSF
Covered when ALL of the following are met:
References age/FDA labeling and specialist prescriber requirement
Detailed list of acceptable indications
Initial Therapy — Long-acting CSF
Covered when ALL of the following are met:
References age/FDA labeling and specialist prescriber requirement
Long-acting agents require chemo not on a weekly schedule for prophylaxis indications
Continued Therapy Criteria
Covered when ALL of the following are met:
Continuation requires prior approval or meeting initial criteria plus documentation of recent treatment
For continuation requests, samples are not acceptable evidence of prior treatment and therefore starting therapy on samples is not approvable. Continuation approvals require documentation that the patient was treated with the requested agent within the past 90 days or prior plan authorization for the same agent.
Initial Therapy Requirements
Initial Therapy — short- vs long-acting requirements
Covered when ALL of the following are met:
See agent-specific indication lists for details; compendia-supported indication required
Long-acting agents have additional requirement that chemotherapy not be weekly for prophylaxis indications
Continuation Therapy Requirements
Continuation Therapy — rules for ongoing approvals
Covered when ALL of the following are met:
Approval duration for continuation: 3 months
Provider Actions and Documentation Requirements
Prior authorization required; approval when compendia-supported indication and criteria met
Prior authorization is required; requests are approved when the requested CSF is being used for a compendia-supported indication and all applicable initial or continued therapy criteria are met. Compendia allowed include AHFS‑DI, Clinical Pharmacology, DrugDex (Class I/IIa/IIb), Lexi‑Drugs level A, or NCCN category 1 or 2A.
No step-therapy requirement specified
No explicit step-therapy (failure of another CSF) requirement is stated in the policy; authorization decisions are based on the documented indication, FN risk factors, and prior response as specified in the short- and long-acting agent criteria.
Chart documentation required within 90 days
Provide chart notes within the past 90 days documenting the indication for the requested CSF, the prescriber specialty (e.g., hematology or oncology), and—when requesting continuation—documentation that the patient was treated with the requested agent within the past 90 days; when used for prophylaxis, document relevant febrile neutropenia risk factors.
- Indication as described in initial or continuation criteria (see criteria lists).
- Prescriber specialty consistent with the patient’s diagnosis (e.g., hematology/oncology).
- For continuation: chart evidence of treatment with the requested agent within the past 90 days (samples do not qualify).
- Documentation of FN risk factors when used for primary prophylaxis (e.g., age >65, ANC <100/µL, anticipated neutropenia >10 days, prior FN, etc.).
Denial risk if initial criteria or compendia support are missing
If the request does not show a compendia-supported indication or fails to meet the specific initial therapy requirements (age within FDA labeling/support, required prescriber specialty, and one of the listed qualifying clinical indications), the request is at risk of denial.
- Initial short-acting and long-acting criteria require patient age within FDA labeling or supportive evidence and prescriber specialty.
- A qualifying indication from the policy’s listed indications must be documented.
Denial risk if prior use or prior approval not documented
For continuation requests, absence of prior plan approval or lack of documentation showing the patient was treated with the requested agent within the past 90 days (samples are not acceptable evidence) places the request at risk for denial.
- Continuation requires prior approval through the plan’s PA process or meeting initial therapy criteria.
- Chart notes must show treatment with the requested agent within the past 90 days; starting therapy on samples is not approvable.
Step Therapy / Prior Agent Requirements
| Step | Requirement |
|---|---|
| 1 | No explicit step therapy requirement defined — approval is based on the requested indication, documented FN risk factors, prescriber specialty, and whether initial or continuation criteria are met (see initial and long‑acting agent criteria). |
Definitions and Risk Factors
Agent Examples and Biosimilar Notes
Filgrastim: short-acting CSF treated under short-acting criteria
Filgrastim (reference) is listed as a short-acting CSF example and is evaluated under the same short-acting agent criteria in the policy.
- Example product: Nivestym (filgrastim-aafi) listed as short-acting CSF
Pegfilgrastim: long-acting CSF treated under long-acting criteria
Pegfilgrastim (reference) is listed as a long-acting CSF example and is evaluated under the same long-acting agent criteria in the policy.
- Example product: Fulphila (pegfilgrastim-jmdb) listed as long-acting CSF
Background
Colony stimulating factors (CSFs), including short- and long-acting agents, are used to reduce the duration of neutropenia, prevent or treat febrile neutropenia (FN), and to mobilize hematopoietic progenitor cells for collection. The policy requires that use for prophylaxis or treatment be supported by compendia or FDA-labeled indications and that prescribers document patient-specific FN risk factors when applicable.
When used as primary prophylaxis, CSF use is determined by the chemotherapy-associated FN risk and individual patient risk factors; for example, agents are covered for primary prophylaxis when the chemotherapy FN risk is >20%, or when lower chemotherapy FN risk is present but the prescriber documents one or more patient risk factors. For continuation of therapy the policy requires prior approval or documentation of recent treatment within the past 90 days.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.